文献速递心境障碍焦虑、强迫与应激相关障碍精神分裂症与精神病性障碍

口服糖皮质激素与精神疾病及自杀行为结局风险:基于人群的队列研究

Oral glucocorticoids and risk of psychiatric and suicidal behaviour outcomes: population-based cohort study.
PubMed 文献 · Br J Psychiatry · 2025-06-25

结果显示治疗期间抑郁、双相、焦虑等精神疾病结局风险升高,但未发现与自杀行为的明确关联;有精神疾病史者绝对发生率更高。

要点

  • 口服糖皮质激素治疗期间,双相障碍(HR 1.23)和焦虑障碍(HR 1.25)风险升高最明显。
  • 未发现糖皮质激素治疗与自杀行为之间存在明确关联(HR 1.06,95%CI 0.96-1.17)。
  • 有精神疾病史的患者治疗期间精神结局绝对发生率更高,可能需要额外监测。

核心结论

  • 口服糖皮质激素治疗与严重精神疾病结局风险升高相关,包括常见精神障碍的起病和复发。
  • 未发现糖皮质激素治疗与自杀行为之间存在明确关联。
  • 有精神疾病史者治疗期间精神结局绝对发生率更高,可能需要额外监测。

研究设计与样本

  • 采用仅用药队列的Cox比例风险模型进行个体内比较,比较治疗期间与非治疗期间结局发生率。
  • 另采用目标试验模拟方法,在自身免疫或胃肠自身免疫疾病诊断个体中比较启动与未启动糖皮质激素者的结局风险。

主要发现

  • 个体内风险比从抑郁障碍的1.08(95%CI 1.00-1.16)到双相障碍的1.23(95%CI 1.12-1.36)和焦虑障碍的1.25(95%CI 1.20-1.31)。
  • 自杀行为风险比为1.06(95%CI 0.96-1.17),无明确关联。
  • 按年龄和性别分层后结果相似;在自身免疫疾病诊断者中个体内关联减弱。
  • 焦虑和双相障碍结局风险在治疗最初几周似乎尤其升高。
  • 治疗期间绝对发生率轻度升高,有精神疾病史者更高。

临床怎么用

  • 临床医生应知晓口服糖皮质激素治疗期间精神疾病结局风险升高,尤其焦虑和双相障碍在治疗早期。
  • 对有精神疾病史的患者,在糖皮质激素治疗期间可考虑额外监测精神症状。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite evidence of associations between glucocorticoid treatment and adverse psychiatric and suicidal behaviour outcomes, large-scale observational evidence for serious outcomes is lacking. AIMS: To assess the risk of psychiatric and suicidal behaviour outcomes during glucocorticoid treatment. METHOD: Using Swedish population registers, we identified 1 105 964 individuals aged 15-54 years who collected a glucocorticoid prescription in oral form between 2006 and 2020. We investigated associations with a range of psychiatric outcomes: unplanned specialist healthcare contacts due to depressive, bipolar, anxiety or schizophrenia-spectrum disorders; and deaths by suicide or unplanned specialist healthcare contacts due to self-harm ('suicidal behaviour'). We estimated hazard ratios from Cox proportional hazards models in a medication-only cohort by comparing outcome rates during and outside treated periods within individuals. We further identified individuals with an autoimmune or gastrointestinal autoimmune disorder diagnosis and compared hazards of the outcomes between those who did and did not initiate a glucocorticoid using a target trial emulation approach. RESULTS: We found increased risks for psychiatric outcomes, with within-individual hazard ratios ranging from 1.08 (95% CI, 1.00-1.16) for depressive disorders to 1.23 (95% CI, 1.12-1.36) for bipolar disorder and 1.25 (95% CI, 1.20-1.31) for anxiety disorders. We found no clear association with suicidal behaviour (hazard ratio: 1.06; 95% CI, 0.96-1.17). These findings were similar when stratified by age and gender. Within-individual associations were attenuated in those diagnosed with an autoimmune disorder. The risk of anxiety and bipolar disorder outcomes appeared particularly elevated in the first weeks of treatment. Absolute rates were modestly elevated during treatment, and higher in those with a history of psychiatric disorders. CONCLUSIONS: Glucocorticoid treatment is associated with elevated risks of serious psychiatric outcomes, including the onset and relapse of common psychiatric disorders. Individuals with psychiatric histories may require additional monitoring during glucocorticoid treatment.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lagerberg T, Gustafsson TT, Molero Y, et al. Oral glucocorticoids and risk of psychiatric and suicidal behaviour outcomes: population-based cohort study. Br J Psychiatry. 2025. PMID: 40556309. doi:10.1192/bjp.2025.128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。